

CHEMICAL HERITAGE FOUNDATION

HUGH A. D'ANDRADE

Transcript of an Interview
Conducted by

Sally Smith Hughes and Leo Slater

at

Madison, New Jersey

on

6 November 1998

(With Subsequent Corrections and Additions)

The Chemical Heritage Foundation
315 Chestnut St.
Philadelphia, PA 19106-2702

Regional Oral History Office
The Bancroft Library
University of California
Berkeley, CA 94720

Biotechnology Oral History Project: Patterns of Regional Growth

I, Hugh A. Dandrade, do hereby give to the
name)
Regents of the University of California and the Chemical Heritage
Foundation for such scholarly and educational uses as the
Director of The Bancroft Library and the President of the
Chemical Heritage Foundation shall determine the following tape-
recorded interview(s) recorded with me on 06 NOV 1938 [1998]
date(s)

for the Bancroft Library and the Chemical Heritage Foundation as
an unrestricted gift and transfer to the Regents of the University
of California and the Chemical Heritage Foundation jointly legal
title and all literary property rights including copyright. This
gift does not preclude any use which I may want to make of the
information in the recordings.

This agreement may be revised or amended by mutual consent
of the parties undersigned.

C. B. Faulhaber
Director
The Bancroft Library

Hugh A. Dandrade
Signature

12/2/98
date

Hugh A. Dandrade, One Ginalda Farms
name/address of interviewee
Madison, NJ 07140

Arnold Thadomy
President
Chemical Heritage Foundation

11/6/98
date

4 November 98
date

Subject of
interview(s) Regional Biotechnology: Schering-Plough, Biogen,
DNAX

This interview has been designated as **Free Access**.

One may view, quote from, cite, or reproduce the oral history with the permission of CHF.

Please note: Users citing this interview for purposes of publication are obliged under the terms of the Chemical Heritage Foundation Oral History Program to credit CHF using the format below:

Hugh A. D'Andrade, interview by Sally Smith Hughes and Leo Slater at Madison, New Jersey, 6 November 1998 (Philadelphia: Chemical Heritage Foundation, Oral History Transcript # 0172).



Chemical Heritage Foundation
Oral History Program
315 Chestnut Street
Philadelphia, Pennsylvania 19106



The Chemical Heritage Foundation (CHF) serves the community of the chemical and molecular sciences, and the wider public, by treasuring the past, educating the present, and inspiring the future. CHF maintains a world-class collection of materials that document the history and heritage of the chemical and molecular sciences, technologies, and industries; encourages research in CHF collections; and carries out a program of outreach and interpretation in order to advance an understanding of the role of the chemical and molecular sciences, technologies, and industries in shaping society.

HUGH A. D'ANDRADE

1938 Born in Metuchen, New Jersey on 7 November

Education

1961 B.A., economics, Rutgers University
1964 LL.B., Columbia University Law School

Professional Experience

1964-1965 Law Secretary to Hon. Frederick W. Hall, Associate Justice of the New Jersey Supreme Court

1965-1968 Associate, Toner, Crowley, Woelper & Vanderbilt

Ciba-Geigy Corporation

1968-1970 General Attorney, Ciba Corporation
1970-1975 Counsel, Pharmaceuticals Division
1975-1977 Vice President and Counsel, Pharmaceuticals Division
1977-1981 Vice President, Administration and Counsel, Pharmaceuticals Division

Schering-Plough Corporation

1981-1984 Senior Vice President, Administration
1984-1995 Executive Vice President, Administration
1996-present Vice Chairman and Chief Administrative Officer

ABSTRACT

Hugh A. D'Andrade begins the interview with a brief discussion of his education and early career. D'Andrade began his career in corporate law as General Attorney for the Ciba-Geigy Corporation in 1968. By 1977, he had risen through the ranks to become Vice President of Administration and Counsel of the Pharmaceuticals Division. In 1981, he joined Schering-Plough Corporation as Senior Vice-President of Administration. During D'Andrade's first years with Schering, the company worked with Cetus Corporation on antibiotic screening, and also worked with Biogen on interferon and erythropoietin. D'Andrade served as Schering's representative on Biogen's board for six years, where he worked closely with Charles Weissmann, Walter Gilbert, Bernard Mach, Philip Sharp, and Walter Fiers. D'Andrade worked on the development side of the interferon project and was instrumental in patent negotiations with Roche. D'Andrade discusses the presence of biotechnology in New Jersey and its relationship to other biotechnology organizations across the country. He concludes the interview with a discussion on the acquisition of DNAX, and his involvement with Biotechnology Industry Organization (BIO) and the Industrial Biotechnology Association (IBA).

INTERVIEWERS

Sally Smith Hughes graduated from the University of California, Berkeley in 1963 with an A.B. in zoology. She received her M.A. in Anatomy from the University of California, San Francisco in 1966. In 1972, she earned her Ph.D. in the history of science and medicine from the Royal Postgraduate Medical School, University of London. She served a Postgraduate Research Histologist with the Cardiovascular Research Institute at the University of California, San Francisco from 1966-1969, and as science historian for the History of Science and Technology program at the Bancroft Library from 1978-1980. Dr. Hughes was an Othmer Fellow at the Chemical Heritage Foundation in 1997. She is presently Research Historian and Principal Editor on medical and scientific topics for the Regional Oral History Office at the University of California, Berkeley. She is author of *The Virus: A History of the Concept*, and is currently interviewing and writing in the fields of AIDS, molecular biology, and biotechnology.

Leo Slater is Director of Historical Services at the Chemical Heritage Foundation in Philadelphia. A former research chemist at the Schering-Plough Research Institute, he received his doctorate in History from Princeton University in 1997.

TABLE OF CONTENTS

- 1 Early Years
 Growing up in Metuchen, New Jersey. Attending college and law school.
 Working for New Jersey Supreme Court Justice. Moving to private firm.
 Beginning career with Ciba-Geigy. Leaving Ciba-Geigy for Schering Plough.
 Schering's relationship with Cetus and Biogen. Moshe Alafi and Robert Luciano.
- 4 Schering-Plough
 Biogen's Board. Working with Philip Sharp, Walter Gilbert, Bernard Mach,
 Walter Fiers, Jeremy Knowles, and Charles Weissmann. Erythropoietin and
 interferon research.
- 11 Research and Development
 Working on interferon development. Obtaining patents. Weissmann patent.
 Biotechnology's presence in United States. Research of Walter Gilbert.
 Enthusiasm of scientists.
- 21 DNAX
 Success of relationship with DNAX. Research on therapeutic proteins.
 Interleukin-10. Emergence of biotechnology.
- 24 Conclusion
 Relationship with Biotechnology Industry Organization (BIO) and the Industrial
 Biotechnology Association (IBA). Carl Feldbaum. Future of biotechnology.
- 28 Index

INDEX

A

ABA, 26
Adenovirus, 23
Alafi, Moshe, 2-4
Alzheimer's disease, 12
American Cyanamid Company, 2
Amgen, 10, 17
Amsterdam, The Netherlands, 6-7
Anti-IL-2, 23
Association of Biotechnology Companies (ABC), 26
Autoimmune disease, 21

B

Basel, Switzerland, 3-4, 18
Bein, Hugo, 3
Berg, Paul, 18, 20, 24
Biogen, 3-7, 9-11, 13-14, 17, 22-24
Biotechnology Industry Organization (BIO), 24-26
Bloomfield, New Jersey, 7, 19
Boston, Massachusetts, 17-18
Boyer, Herbert W., 18, 20, 24

C

Cambridge, Massachusetts, 16-17, 25
Canji, 23, 27
Cantell, Kari, 4
Centocor, 12, 17, 23
Cephalon, Inc., 12
Cetus Corporation, 2, 4, 11, 17, 24
Chemokines, 22
Ciba-Geigy Corporation, 1-4, 25
 Pharmaceutical Division, 1
Clinton, President William Jefferson, 26
Cohen-Boyer patent, 15
Columbia University
 Law School, 1
Crohn's disease, 23
Cytokines, 22

D

Denver, Colorado, 16, 18
Deoxyribonucleic acid (DNA), 5, 7, 24
DNAX, 11-13, 19-23, 27

E

E. coli, 7
Eli Lilly and Company, 3
Erythropoietin, 4, 6-7, 9-11, 16

F

Feldbaum, Carl B., 26
Fiers, Walter, 6-9
Food and Drug Administration (FDA), 1, 3, 26

G

Gene therapy, 23, 27
Genentech, 4, 10, 12, 14-15, 17, 25
Genetics Institute, 17, 20, 24
Geneva, Switzerland, 6-8, 10-11
Gilbert, Walter, 6-10, 13, 17-20, 24
Glycosylation, 13
Granulocyte-colony stimulating factor (G-CSF), 16

H

Harvard University, 6-7, 18-20
Hepatitis C, 16
Hoffmann-La Roche Ltd., 10, 14, 18, 27
Hood, Leroy, 20, 24
Houston, Texas, 16
Human Genome Sciences, 17, 23, 26
Hybridomas, 5

I

IL-2, 17, 21, 23
IL-10, 27
Immunex, 17, 23
Incyte, 23
Industrial Biotechnology Association (IBA), 24-26
Interferon, 4-7, 9-10, 12-16, 21, 23-24, 27
Interleukins, 17
 Interleukin-10, 23

K

Kaposi's sarcoma, 16
Knowles, Jeremy, 6-7
Kogan, Richard, 22
Kornberg, Arthur, 18, 20-22, 24

L

Lane, Alex, 4
Larrison, Douglas, 4
Lederle-Hermetic Company, 2
Lennen, Irwin, 14
Luciano, Robert P., 2-6, 11, 14, 21-22
Lymphokines, 22

M

Mach, Bernard, 6-9
Malvern, Pennsylvania, 17
Massachusetts Institute of Technology (MIT), 7, 18
Menlo Park, New Jersey, 17
Merck & Co., 3, 17-20, 23, 27
Methionines, 13
Metuchen, New Jersey, 1
Monsanto Company, 25

N

Nagabhushan, Tattanahalli L., 13
Nature, 5, 18
New Brunswick, New Jersey, 1
New Jersey Supreme Court, 1
New York City, New York, 18
Newark, New Jersey, 1

P

Palo Alto, California, 16-18
Peska, 14
Pfizer, 3, 17, 23
Pharmaceutical Manufacturer's Association (PMA), 25-26
Pharmacopeia, 22-23, 26
PNAS, 18
Pro-inflammatory cytokines, 21, 23
Proteins, 5, 10-11, 21-23

R

Rahway, New Jersey, 18-19
Regeneron, 12
Rheumatoid arthritis, 23
Rifkin, Jeremy, 25

S

San Diego, California, 16-17
San Francisco, California, 18
Schering-Plough Corporation, 1-5, 9, 11-14, 20-25, 27
Science, 4-5, 18, 24
Scientific American, 4
Scotland, University of, 6
Seattle, Washington, 17
Sharp, Philip, 6-7, 10, 13, 18, 20, 24
Stanford University, 6, 18-19
Steinberg, Walter, 17
Summit, New Jersey, 1, 3-4
Swanson, Robert, 18

T

Tanangucci, --, 6
T-cell, 21

U

U.S. Patent Office, 14

V

Vertex, 17

W

Warner-Lambert Laboratories, 17
Washington, DC, 26
Weissmann, Charles, 6-15, 18, 24
Woodward, Robert Burns, 18-19

Z

Zaffaroni, Alejandro, 21
Zurich, Switzerland, 6-7